INS and diabetes mellitus: The role of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin-receptor blockers (ARB) in glycaemic control and the development of diabetes has long been noted, but the mechanisms for improving glucose tolerance and insulin sensitivity by inhibiting the renin-angiotensin system are complex and unclear.